source
- STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting downRecent deaths are setbacks in drug companies’ interest in applying cancer therapy strategies to autoimmune diseases.STAT · 13d ago↗ source
- Artiva to quit autoimmune cell therapy work, cut staff after patient deathsThe disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.BioPharma Dive · 13d ago↗ source
- Roche's KRAS inhibitor divarasib shows strong results in second-line lung cancer trial at ESMORoche presented data from a trial of its KRAS G12C inhibitor divarasib at the European Society for Medical Oncology meeting. The study evaluated divarasib in patients with advanced non-small cell…